The FDA has approved them to treat Type 2 diabetes and obesity, but many conditions, including Type 1 diabetes, lack approval
Horne, B
2007 Jan 16;104(3):937-42
By helping to lower systemic oxidative stress, glutathione may help quiet this neuroinflammatory alarm
Patients travel easily with oral sprays, do not need to dispose of biohazardous sharps, and maintain high compliance over months or years
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including exenatide, liraglutide, and semaglutide, have shown promise in reducing body weight, improving glycemic control, and slowing the progression of cardiovascular and kidney diseases